Skip to main content
main-content

Zeitschrift

Investigational New Drugs

Investigational New Drugs 1/2018

Ausgabe 1/2018

Inhaltsverzeichnis ( 21 Artikel )

08.09.2017 | PRECLINICAL STUDIES | Ausgabe 1/2018

AN-7, a butyric acid prodrug, sensitizes cutaneous T-cell lymphoma cell lines to doxorubicin via inhibition of DNA double strand breaks repair

Lilach Moyal, Neta Goldfeiz, Batia Gorovitz, Ada Rephaeli, Efrat Tal, Nataly Tarasenko, Abraham Nudelman, Yael Ziv, Emmilia Hodak

17.08.2017 | PRECLINICAL STUDIES | Ausgabe 1/2018

CUDC-907, a dual HDAC and PI3K inhibitor, reverses platinum drug resistance

Kenneth K. W. To, Li-wu Fu

05.09.2017 | PRECLINICAL STUDIES | Ausgabe 1/2018

Crucial microRNAs and genes in metformin’s anti-pancreatic cancer effect explored by microRNA-mRNA integrated analysis

Yilong Li, Le Li, Guangquan Zhang, Yongwei Wang, Hua Chen, Rui Kong, Shangha Pan, Bei Sun

30.09.2017 | PRECLINICAL STUDIES | Ausgabe 1/2018

The kinesin Eg5 inhibitor K858 induces apoptosis and reverses the malignant invasive phenotype in human glioblastoma cells

Ludovica Taglieri, Giovanna Rubinacci, Anna Giuffrida, Simone Carradori, Susanna Scarpa

17.04.2017 | PHASE I STUDIES | Ausgabe 1/2018

A phase I dose-escalation study of the safety and pharmacokinetics of a tablet formulation of voxtalisib, a phosphoinositide 3-kinase inhibitor, in patients with solid tumors

Janice M. Mehnert, Gerald Edelman, Mark Stein, Heather Camisa, Joanne Lager, Jean-François Dedieu, Anne-Frédérique Ghuysen, Jyoti Sharma, Li Liu, Patricia M. LoRusso

02.05.2017 | PHASE I STUDIES | Ausgabe 1/2018

Phase I study of Nedaplatin, a platinum based antineoplastic drug, combined with nab-paclitaxel in patients with advanced squamous non–small cell lung cancer

Satoshi Igawa, Sakiko Otani, Yoshiro Nakahara, Shinichiro Ryuge, Yasuhiro Hiyoshi, Tomoya Fukui, Hisashi Mitsufuji, Masaru Kubota, Masato Katagiri, Yuichi Sato, Jiichiro Sasaki, Noriyuki Masuda

15.06.2017 | PHASE I STUDIES | Ausgabe 1/2018 Open Access

A phase Ib study of everolimus combined with metformin for patients with advanced cancer

Remco J. Molenaar, Tim van de Venne, Mariëtte J. Weterman, Ron A. Mathot, Heinz-Josef Klümpen, Dick J. Richel, Johanna W. Wilmink

09.06.2017 | PHASE I STUDIES | Ausgabe 1/2018

Outcomes and prognostic factors for relapsed or refractory lymphoma patients in phase I clinical trials

Jean-Marie Michot, Lina Benajiba, Laura Faivre, Capucine Baldini, Lelia Haddag, Clement Bonnet, Christophe Massard, Frederic Bigot, Camille Bigenwald, Benjamin Verret, Zoé A. P. Thomas, Andrea Varga, Anas Gazzah, Antoine Hollebecque, David Ghez, Julien Lazarovici, Rastilav Balheda, Aurore Jeanson, Sophie Postel-Vinay, Alina Danu, Jean-Charles Soria, Xavier Paoletti, Vincent Ribrag

28.07.2017 | PHASE I STUDIES | Ausgabe 1/2018

A Phase I study to determine safety, pharmacokinetics, and pharmacodynamics of ANF-RHO™, a novel PEGylated granulocyte colony-stimulating factor, in healthy volunteers

Hemant Misra, John Berryman, Ronald Jubin, Abraham Abuchowski

20.07.2017 | PHASE I STUDIES | Ausgabe 1/2018

Phase I dose escalation study of NMS-1286937, an orally available Polo-Like Kinase 1 inhibitor, in patients with advanced or metastatic solid tumors

Glen J. Weiss, Gayle Jameson, Daniel D. Von Hoff, Barbara Valsasina, Cristina Davite, Claudia Di Giulio, Francesco Fiorentini, Rachele Alzani, Patrizia Carpinelli, Alessandro Di Sanzo, Arturo Galvani, Antonella Isacchi, Ramesh K. Ramanathan

08.11.2017 | PHASE II STUDIES | Ausgabe 1/2018

Phase Ib/II study of gemcitabine, nab-paclitaxel, and pembrolizumab in metastatic pancreatic adenocarcinoma

Glen J. Weiss, Lisa Blaydorn, Julia Beck, Kirsten Bornemann-Kolatzki, Howard Urnovitz, Ekkhard Schütz, Vivek Khemka

11.11.2017 | PHASE II STUDIES | Ausgabe 1/2018

A phase 2 study of ontuxizumab, a monoclonal antibody targeting endosialin, in metastatic melanoma

Sandra P. D’Angelo, Omid A. Hamid, Ahmad Tarhini, Dirk Schadendorf, Bartosz Chmielowski, Frances A. Collichio, Anna C. Pavlick, Karl D. Lewis, Susan C. Weil, John Heyburn, Charles Schweizer, Daniel J. O’Shannessy, Richard D. Carvajal

23.11.2017 | PHASE II STUDIES | Ausgabe 1/2018

Phase II study of doxorubicin and thalidomide in patients with refractory aggressive fibromatosis

Xin Liu, Huijie Wang, Xianghua Wu, Xiaonan Hong, Zhiguo Luo

13.10.2017 | REVIEW | Ausgabe 1/2018

Clinical toxicity of antibody drug conjugates: a meta-analysis of payloads

Joanna C. Masters, Dana J. Nickens, Dawei Xuan, Ronald L. Shazer, Michael Amantea

28.10.2017 | REVIEW | Ausgabe 1/2018

Ganoderic acid, lanostanoid triterpene: a key player in apoptosis

Balraj Singh Gill, Navgeet, Richa Mehra, Vicky Kumar, Sanjeev Kumar

20.06.2017 | SHORT REPORT | Ausgabe 1/2018

A case of nivolumab-related cholangitis and literature review: how to look for the right tools for a correct diagnosis of this rare immune-related adverse event

Francesco Gelsomino, Giovanni Vitale, Andrea Ardizzoni

28.06.2017 | SHORT REPORT | Ausgabe 1/2018

Chemotherapy-induced cardiomyopathy caused by Pemetrexed

Takuya Oyakawa, Kei Iida, Masatoshi Kusuhara, Hirotsugu Kenmotsu, Takashi Sugino

21.07.2017 | SHORT REPORT | Ausgabe 1/2018

Feasibility of olanzapine, multi acting receptor targeted antipsychotic agent, for the prevention of emesis caused by continuous cisplatin- or ifosfamide-based chemotherapy

Seiko Bun, Kan Yonemori, Toru Akagi, Emi Noguchi, Tatsunori Shimoi, Akihiko Shimomura, Mayu Yunokawa, Chikako Shimizu, Yasuhiro Fujiwara, Yoshinori Makino, Yoshikazu Hayashi, Kenji Tamura

01.08.2017 | SHORT REPORT | Ausgabe 1/2018

Addition of an antiangiogenic therapy, bevacizumab, to gemcitabine plus oxaliplatin improves survival in advanced biliary tract cancers

Marie Bréchon, Marie Dior, Johann Dréanic, Bertrand Brieau, Marie-Anne Guillaumot, Catherine Brezault, Olivier Mir, François Goldwasser, Romain Coriat

07.08.2017 | SHORT REPORT | Ausgabe 1/2018

Germline BRCA mutations in Asian patients with pancreatic adenocarcinoma: a prospective study evaluating risk category for genetic testing

Kyoungmin Lee, Changhoon Yoo, Kyu-pyo Kim, Kyoung-Jin Park, Heung-Moon Chang, Tae Won Kim, Jae-Lyun Lee, Woochang Lee, Sang Soo Lee, Do Hyun Park, Tae Jun Song, Dong Wan Seo, Sung Koo Lee, Myung-Hwan Kim, Sang Hyun Shin, Dae Wook Hwang, Ki Byung Song, Jae Hoon Lee, Song Cheol Kim, Baek-Yeol Ryoo

29.01.2018 | ACKNOWLEDGEMENTS | Ausgabe 1/2018

Acknowledgement of Reviewers 2017

Aktuelle Ausgaben

Neu im Fachgebiet Onkologie

Mail Icon II Newsletter

Bestellen Sie unseren kostenlosen Newsletter Update Onkologie und bleiben Sie gut informiert – ganz bequem per eMail.

Bildnachweise